Hormonal
Intensive glycemic control (targeting HbA1c ≤ 6.5%) does not significantly reduce cardiovascular events or all-cause mortality in patients with Type 2 Diabetes compared to standard control, and may increase mortality risk.
If you have Type 2 Diabetes, aiming for extremely low blood sugar (like an A1c under 6.5%) may not protect your heart and could actually increase your risk of death or severe low-blood-sugar episodes. Focus on standard control targets (around 7%) and managing blood pressure and cholesterol instead, unless your doctor advises otherwise based on your specific health history.
Current studies fail to show that intensive glycemic control (HbA1c ≤ 6.5%) has a significant CV benefit compared to standard glycemic control targets (HbA1c of 7%-7.9%) in patients with T2DM... Furthermore, very tight glycemic control (HbA1c ≤ 6%), as seen in the ACCORD trial, may place patients at additional risk of hypoglycemia, weight gain and all cause mortality.
Why this rating
Based on multiple large-scale, multi-center randomized control trials (UKPDS, VADT, ADVANCE, ACCORD, DCCT/EDIC).
Source
Diabetes and cardiovascular disease: Epidemiology, biological mechanisms, treatment recommendations and future research
Benjamin M Leon · World Journal of Diabetes · 2015
DOI 10.4239/wjd.v6.i13.1246
More from this paper
- Intensive glycemic control (targeting HbA1c ≤ 7%) significantly reduces cardiovascular events and microvascular complications in patients with Type 1 Diabetes.Strong
- Statins significantly reduce cardiovascular events, all-cause mortality, and stroke in patients with Type 2 Diabetes, regardless of baseline cholesterol levels.Strong
- Intensive blood pressure control (targeting systolic BP < 120 mmHg) does not reduce fatal or nonfatal major cardiovascular events in patients with Type 2 Diabetes compared to standard control (< 140 mmHg) and increases adverse events.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →